結合奈米微脂體複合迷迭香酸與近紅外線光於帕金森氏症之研究

Abstract

隨著人口逐年老化，帕金森氏症患者數量亦隨之增加，目前無有效根治帕金森氏症之治療方法，大部分治療策略為提升多巴胺神經元中之多巴胺濃度以緩解帕金森氏症之症狀，但隨疾病症狀之發展，治療效果亦隨之逐漸下降，因目前治療策略之局限性，故需發展新治療策略以應對帕金森氏症治療之挑戰。 本研究提出帕金森氏症之新治療方式，開發奈米微脂體複合迷迭香酸之奈米藥物材料，亦結合近紅外光之光生物調節治療，此方法藉具抗氧化性之天然藥物迷迭香酸抑制活性氧化物質之產生，藉微脂體包覆天然藥物可增加藥物穩定度、藥物遞送率及生物利用度，而藉粒線體複合物 IV 於近紅外光之吸收，增強電子傳遞鏈之遞送，增加三磷酸腺苷之生成，以抑制細胞之凋亡，本研究藉開發之奈米微脂體複合迷迭香酸、近紅外光及奈米微脂體複合迷迭香酸結合近紅外光之治療方式，應用於魚藤酮誘導之帕金森氏症細胞模型，探討方法於帕金森氏症治療之可行性。 本研究提出之奈米微脂體複合迷迭香酸之藥物治療結合近紅外光之光生物調節治療方式於魚藤酮誘導之帕金森模型具最高21%之恢復率，此方法結合奈米微脂體複合迷迭香酸之抗氧化治療與近紅外光之光生物調節治療，兩者結合使恢復率增加，表明此方式具治療帕金森氏症之潛力。

As the population ages, the number of Parkinson's disease patients increases, and there is no effective cure. Most treatments aim to increase dopamine levels to relieve symptoms, but their effectiveness decreases as the disease progresses. Therefore, new treatment strategies are needed. This study proposes a new treatment for Parkinson's disease by developing a nanodrug material composed of liposome complexes with rosmarinic acid and combined with near-infrared (NIR) photobiomodulation therapy. This method utilizes the antioxidant properties of the rosmarinic acid to inhibit the production of reactive oxygen species. Encapsulating the natural drug in liposomes increases the stability, delivery rate, and bioavailability. Additionally, the absorption of NIR by mitochondrial complex IV enhances electron transport chain activity, increasing adenosine triphosphate production and inhibiting cell apoptosis. This study explores the feasibility of this approach by applying the developed nano-liposome complex with rosmarinic acid, NIR, and their combination to a rotenone-induced Parkinson's disease cell model. The proposed treatment method, combining nano-liposome complex with rosmarinic acid and near-infrared photobiomodulation therapy shows a 21% recovery rate in the rotenone-induced Parkinson's disease model. This method combines the antioxidant treatment of the nano-liposome complex with rosmarinic acid and the photobiomodulation treatment of NIR, resulting in an increased recovery rate, indicating its potential as a therapeutic approach for Parkinson's disease.